Skip to main content

Use of SPARC, EGFR, and VEGFR expression to predict response to nab-paclitaxel (nabP)/carboplatin (C)/bevacizumab (B) chemotherapy in triple-negative metastatic breast cancer (TNMBC).

Publication ,  Conference
Hamilton, EP; Kimmick, GG; Desai, N; Singh, S; Hopkins, JO; Marcom, PK; Chadaram, V; Welch, R; Trieu, VN; Blackwell, KL
Published in: Journal of Clinical Oncology
May 20, 2010

Duke Scholars

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2010

Volume

28

Issue

15_suppl

Start / End Page

1109 / 1109

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hamilton, E. P., Kimmick, G. G., Desai, N., Singh, S., Hopkins, J. O., Marcom, P. K., … Blackwell, K. L. (2010). Use of SPARC, EGFR, and VEGFR expression to predict response to nab-paclitaxel (nabP)/carboplatin (C)/bevacizumab (B) chemotherapy in triple-negative metastatic breast cancer (TNMBC). In Journal of Clinical Oncology (Vol. 28, pp. 1109–1109). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2010.28.15_suppl.1109
Hamilton, E. P., G. G. Kimmick, N. Desai, S. Singh, J. O. Hopkins, P. K. Marcom, V. Chadaram, R. Welch, V. N. Trieu, and K. L. Blackwell. “Use of SPARC, EGFR, and VEGFR expression to predict response to nab-paclitaxel (nabP)/carboplatin (C)/bevacizumab (B) chemotherapy in triple-negative metastatic breast cancer (TNMBC).” In Journal of Clinical Oncology, 28:1109–1109. American Society of Clinical Oncology (ASCO), 2010. https://doi.org/10.1200/jco.2010.28.15_suppl.1109.
Hamilton EP, Kimmick GG, Desai N, Singh S, Hopkins JO, Marcom PK, et al. Use of SPARC, EGFR, and VEGFR expression to predict response to nab-paclitaxel (nabP)/carboplatin (C)/bevacizumab (B) chemotherapy in triple-negative metastatic breast cancer (TNMBC). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010. p. 1109–1109.
Hamilton, E. P., et al. “Use of SPARC, EGFR, and VEGFR expression to predict response to nab-paclitaxel (nabP)/carboplatin (C)/bevacizumab (B) chemotherapy in triple-negative metastatic breast cancer (TNMBC).Journal of Clinical Oncology, vol. 28, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2010, pp. 1109–1109. Crossref, doi:10.1200/jco.2010.28.15_suppl.1109.
Hamilton EP, Kimmick GG, Desai N, Singh S, Hopkins JO, Marcom PK, Chadaram V, Welch R, Trieu VN, Blackwell KL. Use of SPARC, EGFR, and VEGFR expression to predict response to nab-paclitaxel (nabP)/carboplatin (C)/bevacizumab (B) chemotherapy in triple-negative metastatic breast cancer (TNMBC). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010. p. 1109–1109.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2010

Volume

28

Issue

15_suppl

Start / End Page

1109 / 1109

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences